Corticosteroid co-treatment induces resistance to chemotherapy in surgical resections, xenografts and established cell lines of pancreatic cancer
<p>Abstract</p> <p>Background</p> <p>Chemotherapy for pancreatic carcinoma often has severe side effects that limit its efficacy. The glucocorticoid (GC) dexamethasone (DEX) is frequently used as co-treatment to prevent side effects of chemotherapy such as nausea, for p...
Main Authors: | Debatin Klaus-Michael, Edler Lutz, Rittgen Werner, Mattern Jürgen, Cato Andrew CB, Büchler Peter, Kolb Armin, Zhang Chengwen, Büchler Markus W, Friess Helmut, Herr Ingrid |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2006-03-01
|
Series: | BMC Cancer |
Online Access: | http://www.biomedcentral.com/1471-2407/6/61 |
Similar Items
-
New molecular aspects in pathogenesis and progression of pancreatic cancer
by: Büchler Markus W, et al.
Published: (2003-01-01) -
Current State of Vascular Resections in Pancreatic Cancer Surgery
by: Thilo Hackert, et al.
Published: (2015-01-01) -
Invasion and metastasis in pancreatic cancer
by: Büchler Markus W, et al.
Published: (2003-01-01) -
Splenic and portal vein thrombosis in pancreatic metastasis from Renal cell carcinoma
by: Loos Martin, et al.
Published: (2006-05-01) -
A proposal for a new clinical classification of chronic pancreatitis
by: Friess Helmut, et al.
Published: (2009-12-01)